Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues
As a result of the spread of SARS-CoV-2, a global pandemic was declared. Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people with minimal danger of suffering serious complications due to COVID-19. Solid immuno-histopathological evidence demonstrate...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Autoimmunity |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/08916934.2023.2259123 |
| _version_ | 1797638429742202880 |
|---|---|
| author | Panagis Polykretis Alberto Donzelli Janci C. Lindsay David Wiseman Anthony M. Kyriakopoulos Michael Mörz Paolo Bellavite Masanori Fukushima Stephanie Seneff Peter A. McCullough |
| author_facet | Panagis Polykretis Alberto Donzelli Janci C. Lindsay David Wiseman Anthony M. Kyriakopoulos Michael Mörz Paolo Bellavite Masanori Fukushima Stephanie Seneff Peter A. McCullough |
| author_sort | Panagis Polykretis |
| collection | DOAJ |
| description | As a result of the spread of SARS-CoV-2, a global pandemic was declared. Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people with minimal danger of suffering serious complications due to COVID-19. Solid immuno-histopathological evidence demonstrates that the COVID-19 genetic vaccines can display a wide distribution within the body, affecting tissues that are terminally differentiated and far away from the injection site. These include the heart and brain, which may incur in situ production of spike protein eliciting a strong autoimmunological inflammatory response. Due to the fact that every human cell which synthesises non-self antigens, inevitably becomes the target of the immune system, and since the human body is not a strictly compartmentalised system, accurate pharmacokinetic and pharmacodynamic studies are needed in order to determine precisely which tissues can be harmed. Therefore, our article aims to draw the attention of the scientific and regulatory communities to the critical need for biodistribution studies for the genetic vaccines against COVID-19, as well as for rational harm-benefit assessments by age group. |
| first_indexed | 2024-03-11T13:03:24Z |
| format | Article |
| id | doaj.art-59e1c8784d754c04b64e1aab5ef3a501 |
| institution | Directory Open Access Journal |
| issn | 0891-6934 1607-842X |
| language | English |
| last_indexed | 2024-03-11T13:03:24Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Autoimmunity |
| spelling | doaj.art-59e1c8784d754c04b64e1aab5ef3a5012023-11-03T16:27:52ZengTaylor & Francis GroupAutoimmunity0891-69341607-842X2023-12-0156110.1080/08916934.2023.22591232259123Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissuesPanagis Polykretis0Alberto Donzelli1Janci C. Lindsay2David Wiseman3Anthony M. Kyriakopoulos4Michael Mörz5Paolo Bellavite6Masanori Fukushima7Stephanie Seneff8Peter A. McCullough9Allineare Sanità e Salute” FoundationAllineare Sanità e Salute” FoundationToxicology & Molecular Biology, Toxicology Support Services, LLCSynechion, IncInfectious Disease, Nasco AD Biotechnology LaboratoryIndependent researcherIndependent medical researcherFoundation of Learning Health Society InstituteComputer Science and Artificial Intelligence Laboratory, MITCardiology, Truth for Health FoundationAs a result of the spread of SARS-CoV-2, a global pandemic was declared. Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people with minimal danger of suffering serious complications due to COVID-19. Solid immuno-histopathological evidence demonstrates that the COVID-19 genetic vaccines can display a wide distribution within the body, affecting tissues that are terminally differentiated and far away from the injection site. These include the heart and brain, which may incur in situ production of spike protein eliciting a strong autoimmunological inflammatory response. Due to the fact that every human cell which synthesises non-self antigens, inevitably becomes the target of the immune system, and since the human body is not a strictly compartmentalised system, accurate pharmacokinetic and pharmacodynamic studies are needed in order to determine precisely which tissues can be harmed. Therefore, our article aims to draw the attention of the scientific and regulatory communities to the critical need for biodistribution studies for the genetic vaccines against COVID-19, as well as for rational harm-benefit assessments by age group.http://dx.doi.org/10.1080/08916934.2023.2259123covid-19 genetic vaccinesspike proteinantigen presentationautoimmunityhistopathologyimmunohistochemistry |
| spellingShingle | Panagis Polykretis Alberto Donzelli Janci C. Lindsay David Wiseman Anthony M. Kyriakopoulos Michael Mörz Paolo Bellavite Masanori Fukushima Stephanie Seneff Peter A. McCullough Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues Autoimmunity covid-19 genetic vaccines spike protein antigen presentation autoimmunity histopathology immunohistochemistry |
| title | Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues |
| title_full | Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues |
| title_fullStr | Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues |
| title_full_unstemmed | Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues |
| title_short | Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues |
| title_sort | autoimmune inflammatory reactions triggered by the covid 19 genetic vaccines in terminally differentiated tissues |
| topic | covid-19 genetic vaccines spike protein antigen presentation autoimmunity histopathology immunohistochemistry |
| url | http://dx.doi.org/10.1080/08916934.2023.2259123 |
| work_keys_str_mv | AT panagispolykretis autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT albertodonzelli autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT janciclindsay autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT davidwiseman autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT anthonymkyriakopoulos autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT michaelmorz autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT paolobellavite autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT masanorifukushima autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT stephanieseneff autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues AT peteramccullough autoimmuneinflammatoryreactionstriggeredbythecovid19geneticvaccinesinterminallydifferentiatedtissues |